A pilot study of high-dose exisulind in men with biochemical relapse (BCR) of prostate cancer after definitive local therapy treated with intermittent androgen deprivation (IAD).

Authors

Evan Yu

Evan Y. Yu

University of Washington and Seattle Cancer Care Alliance, Seattle, WA

Evan Y. Yu , Kevin F Kuo , Rachel Hunter-Merrill , Roman Gulati , Heather H. Cheng , Jason Frederick Flamiatos , Teresa E Gambol , Suzanne P Hall , Celestia S. Higano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT00283803

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr 209)

DOI

10.1200/jco.2013.31.6_suppl.209

Abstract #

209

Poster Bd #

C15

Abstract Disclosures

Similar Posters

Poster

2012 Genitourinary Cancers Symposium

The influence of daily localization during treatment of prostate cancer on acute toxicity.

The influence of daily localization during treatment of prostate cancer on acute toxicity.

First Author: Peter john Rossi

Poster

2024 ASCO Genitourinary Cancers Symposium

Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.

Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.

First Author: Zin Myint

First Author: Nicholas George Nickols